MYLAN-VERAPAMIL SR TABLET (EXTENDED-RELEASE)
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
03-06-2015
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
VERAPAMIL HYDROCHLORIDE
Tillgänglig från:
MYLAN PHARMACEUTICALS ULC
ATC-kod:
C08DA01
INN (International namn):
VERAPAMIL
Dos:
240MG
Läkemedelsform:
TABLET (EXTENDED-RELEASE)
Sammansättning:
VERAPAMIL HYDROCHLORIDE 240MG
Administreringssätt:
ORAL
Enheter i paketet:
100/500 TAB
Receptbelagda typ:
Prescription
Terapiområde:
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0113846003; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2022-06-13
Produktens egenskaper
_Mylan-Verapamil SR Product Monograph _
_Page 1 of 42 _
PRODUCT MONOGRAPH
PR
MYLAN-VERAPAMIL SR
verapamil hydrochloride sustained-release tablets
120 mg, 180 mg and 240 mg
Antihypertensive Agent
Mylan Pharmaceuticals ULC
Date of Preparation:
85 Advance Road
July 15, 2009
Etobicoke, Ontario
M8Z 2S6
Date of Revision:
June 3, 2015
Submission Control No: 184288
_Mylan-Verapamil SR Product Monograph _
_Page 2 of 42 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................21
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................24
STORAGE AND STABILITY
..........................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................29
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL INFORMATION
..........................................................................31
DETAILED PHARMACOLOGY
..................................................................
Läs hela dokumentet
